Situated in the Beijing Economic-Technological Development Area, Huida Biotechnology is an enterprise with a registered capital of RMB350 million. This enterprise engages in the research and exploitation of cellular immunotherapy. Cellular immunotherapy kills tumors in a patient through the “transformation” of the immunocytes into an “immunocyte corps” and transferring them into the patient’s body in order to prevent the transfer or recrudescence of tumors, prolong survival time and improve the quality of life of the patient. In 2013, cellular immunotherapy was selected to be the “Breakthrough of the Year” by Science. From then on, cellular immunotherapy has drawn extensive attention in the academic world.
The Company has engaged in strategic cooperation with the Institute of Human Virology of the School of Medicine, University of Maryland, with the goal to industrialize the immunotherapy in China.
The IHV of the University of Maryland is one of the foremost authorities on HIV basic research, R&D of HIV drugs and vaccines, animal experiments, as well as clinical diagnosis and treatment in the world; and especially on cellular research. Co-founded by Robert Gallo, MD, director of the of the IHV, and IHV’s Chinese professors and directors, Huida Biotechnology has committed itself to offering both safe and effective cellular immunotherapy-based solutions to Chinese patients.